Adjuvant Chemotherapy in Pancreatic Cancer View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2016

AUTHORS

John P. Neoptolemos , David Cunningham , Francesco Sclafani , Paula Ghaneh

ABSTRACT

Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting. More... »

PAGES

1-34

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2

DOI

http://dx.doi.org/10.1007/978-1-4939-6631-8_43-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090830980


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Professor of Surgery, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7700.0", 
          "name": [
            "Professor of Surgery, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neoptolemos", 
        "givenName": "John P.", 
        "id": "sg:person.0750565077.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "David", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Royal Marsden NHS Foundation Trust, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "The Royal Marsden NHS Foundation Trust, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sclafani", 
        "givenName": "Francesco", 
        "id": "sg:person.0653217174.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653217174.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Professor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, L69 3GE, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "Professor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, L69 3GE, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghaneh", 
        "givenName": "Paula", 
        "id": "sg:person.07372440237.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2016", 
    "datePublishedReg": "2016-01-01", 
    "description": "Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10\u201315% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting.", 
    "editor": [
      {
        "familyName": "Neoptolemos", 
        "givenName": "John P.", 
        "type": "Person"
      }, 
      {
        "familyName": "Urrutia", 
        "givenName": "Raul", 
        "type": "Person"
      }, 
      {
        "familyName": "Abbruzzese", 
        "givenName": "James", 
        "type": "Person"
      }, 
      {
        "familyName": "B\u00fcchler", 
        "givenName": "Markus W.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4939-6631-8_43-2", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4939-6631-8", 
        "978-1-4939-6631-8"
      ], 
      "name": "Pancreatic Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "pancreatic cancer", 
      "survival advantage", 
      "combination therapy", 
      "ESPAC-1 trial", 
      "single-agent gemcitabine", 
      "CONKO-001 study", 
      "ESPAC-3 trial", 
      "JASPAC 01 trial", 
      "ESPAC-4 trial", 
      "combination chemotherapy regimens", 
      "large randomized trials", 
      "adjuvant combination chemotherapy", 
      "phase III study", 
      "level 1 evidence", 
      "better toxicity profile", 
      "clear survival advantage", 
      "curative surgery", 
      "adjuvant setting", 
      "adjuvant chemoradiation", 
      "combination chemoradiation", 
      "GITSG study", 
      "chemoradiation regimen", 
      "ESPAC-1", 
      "adjuvant chemotherapy", 
      "advanced disease", 
      "adjuvant therapy", 
      "adjuvant regimens", 
      "chemotherapy regimens", 
      "most patients", 
      "III study", 
      "randomized study", 
      "combination chemotherapy", 
      "randomized trials", 
      "systemic disease", 
      "poor prognosis", 
      "Western patients", 
      "treatment options", 
      "cancer death", 
      "folinic acid", 
      "survival differences", 
      "chemoradiation", 
      "toxicity profile", 
      "chemotherapy", 
      "gemcitabine", 
      "combination studies", 
      "patients", 
      "major cause", 
      "therapy", 
      "trials", 
      "cancer", 
      "Japanese population", 
      "capecitabine", 
      "resection", 
      "regimen", 
      "regimens", 
      "surgery", 
      "disease", 
      "EORTC", 
      "recurrence", 
      "prognosis", 
      "follow", 
      "study", 
      "setting", 
      "death", 
      "survival", 
      "intervention", 
      "cause", 
      "options", 
      "population", 
      "FA", 
      "evidence", 
      "differences", 
      "results", 
      "contrast", 
      "acid", 
      "profile", 
      "use", 
      "S1", 
      "number", 
      "advantages", 
      "observations", 
      "superiority", 
      "justification"
    ], 
    "name": "Adjuvant Chemotherapy in Pancreatic Cancer", 
    "pagination": "1-34", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090830980"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4939-6631-8_43-2"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4939-6631-8_43-2", 
      "https://app.dimensions.ai/details/publication/pub.1090830980"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_85.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4939-6631-8_43-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-6631-8_43-2'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      22 PREDICATES      108 URIs      101 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4939-6631-8_43-2 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nb3ca7ff5c335402790dc22769a208113
4 schema:datePublished 2016
5 schema:datePublishedReg 2016-01-01
6 schema:description Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease, and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or distantly. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using 5-fluorouracil/folinic acid (5FU/FA), S-1, gemcitabine or gemcitabine plus capecitabine, and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow-on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The RTOG 9704 combination study did not demonstrate a survival difference between a 5FU-based regimen compared with a gemcitabine-based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA and single-agent gemcitabine based on the results from the ESPAC-1 and CONKO-001 study, respectively. The ESPAC-3 trial showed that these adjuvant regimens are equally effective, but gemcitabine has a better toxicity profile. In contrast, in a Japanese population, the JASPAC-01 trial demonstrated the superiority of S1 over gemcitabine. Adjuvant combination chemotherapy with gemcitabine plus capecitabine has been recently shown to provide a survival advantage compared with gemcitabine alone in Western patients in the ESPAC-4 trial. Phase III studies investigating other combination chemotherapy regimens are ongoing and will possibly increase the number of treatment options in this setting.
7 schema:editor N54d7e230218d4540995c990027399cc3
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N1b58ee181c354069a80d6c802dc4e2b6
11 schema:keywords CONKO-001 study
12 EORTC
13 ESPAC-1
14 ESPAC-1 trial
15 ESPAC-3 trial
16 ESPAC-4 trial
17 FA
18 GITSG study
19 III study
20 JASPAC 01 trial
21 Japanese population
22 S1
23 Western patients
24 acid
25 adjuvant chemoradiation
26 adjuvant chemotherapy
27 adjuvant combination chemotherapy
28 adjuvant regimens
29 adjuvant setting
30 adjuvant therapy
31 advanced disease
32 advantages
33 better toxicity profile
34 cancer
35 cancer death
36 capecitabine
37 cause
38 chemoradiation
39 chemoradiation regimen
40 chemotherapy
41 chemotherapy regimens
42 clear survival advantage
43 combination chemoradiation
44 combination chemotherapy
45 combination chemotherapy regimens
46 combination studies
47 combination therapy
48 contrast
49 curative surgery
50 death
51 differences
52 disease
53 evidence
54 folinic acid
55 follow
56 gemcitabine
57 intervention
58 justification
59 large randomized trials
60 level 1 evidence
61 major cause
62 most patients
63 number
64 observations
65 options
66 pancreatic cancer
67 patients
68 phase III study
69 poor prognosis
70 population
71 profile
72 prognosis
73 randomized study
74 randomized trials
75 recurrence
76 regimen
77 regimens
78 resection
79 results
80 setting
81 single-agent gemcitabine
82 study
83 superiority
84 surgery
85 survival
86 survival advantage
87 survival differences
88 systemic disease
89 therapy
90 toxicity profile
91 treatment options
92 trials
93 use
94 schema:name Adjuvant Chemotherapy in Pancreatic Cancer
95 schema:pagination 1-34
96 schema:productId N25a104310171484293829ee4434444e6
97 N8caf7bba329143f09b5854fac1104a02
98 schema:publisher Nf0a4058fc6ba42798702c72ee6f45bad
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090830980
100 https://doi.org/10.1007/978-1-4939-6631-8_43-2
101 schema:sdDatePublished 2022-12-01T06:55
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N3416498e1b6141f6900940b51a91d24f
104 schema:url https://doi.org/10.1007/978-1-4939-6631-8_43-2
105 sgo:license sg:explorer/license/
106 sgo:sdDataset chapters
107 rdf:type schema:Chapter
108 N12c7c6b8916c4801b9520bc46093c49f schema:familyName Büchler
109 schema:givenName Markus W.
110 rdf:type schema:Person
111 N1b58ee181c354069a80d6c802dc4e2b6 schema:isbn 978-1-4939-6631-8
112 schema:name Pancreatic Cancer
113 rdf:type schema:Book
114 N1daa85cf42cd4f0485ddfebb060c810b rdf:first sg:person.01320161130.16
115 rdf:rest Nb0b78276584c4884bbf3a35700fb9ea7
116 N25a104310171484293829ee4434444e6 schema:name doi
117 schema:value 10.1007/978-1-4939-6631-8_43-2
118 rdf:type schema:PropertyValue
119 N3416498e1b6141f6900940b51a91d24f schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 N37741cda909c4166af4160e35a4c2b6d rdf:first Nff4a02c1612d4d438025b4ec680486e1
122 rdf:rest N99898f2e68164ee997596ee96057c829
123 N3c9265e445784901aa8a24a73134fb68 rdf:first N12c7c6b8916c4801b9520bc46093c49f
124 rdf:rest rdf:nil
125 N54d7e230218d4540995c990027399cc3 rdf:first N77e52d76030a40acab89968dcd9a1957
126 rdf:rest N37741cda909c4166af4160e35a4c2b6d
127 N77e52d76030a40acab89968dcd9a1957 schema:familyName Neoptolemos
128 schema:givenName John P.
129 rdf:type schema:Person
130 N8caf7bba329143f09b5854fac1104a02 schema:name dimensions_id
131 schema:value pub.1090830980
132 rdf:type schema:PropertyValue
133 N99898f2e68164ee997596ee96057c829 rdf:first Nc78eb3047a324a13921602ff19f3d8ad
134 rdf:rest N3c9265e445784901aa8a24a73134fb68
135 Nb0b78276584c4884bbf3a35700fb9ea7 rdf:first sg:person.0653217174.51
136 rdf:rest Nedb4ae0372a64287bdcb004f23daba13
137 Nb3ca7ff5c335402790dc22769a208113 rdf:first sg:person.0750565077.18
138 rdf:rest N1daa85cf42cd4f0485ddfebb060c810b
139 Nc78eb3047a324a13921602ff19f3d8ad schema:familyName Abbruzzese
140 schema:givenName James
141 rdf:type schema:Person
142 Nedb4ae0372a64287bdcb004f23daba13 rdf:first sg:person.07372440237.86
143 rdf:rest rdf:nil
144 Nf0a4058fc6ba42798702c72ee6f45bad schema:name Springer Nature
145 rdf:type schema:Organisation
146 Nff4a02c1612d4d438025b4ec680486e1 schema:familyName Urrutia
147 schema:givenName Raul
148 rdf:type schema:Person
149 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
150 schema:name Medical and Health Sciences
151 rdf:type schema:DefinedTerm
152 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
153 schema:name Oncology and Carcinogenesis
154 rdf:type schema:DefinedTerm
155 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.5072.0
156 schema:familyName Cunningham
157 schema:givenName David
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
159 rdf:type schema:Person
160 sg:person.0653217174.51 schema:affiliation grid-institutes:grid.5072.0
161 schema:familyName Sclafani
162 schema:givenName Francesco
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653217174.51
164 rdf:type schema:Person
165 sg:person.07372440237.86 schema:affiliation grid-institutes:grid.10025.36
166 schema:familyName Ghaneh
167 schema:givenName Paula
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86
169 rdf:type schema:Person
170 sg:person.0750565077.18 schema:affiliation grid-institutes:grid.7700.0
171 schema:familyName Neoptolemos
172 schema:givenName John P.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18
174 rdf:type schema:Person
175 grid-institutes:grid.10025.36 schema:alternateName Professor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, L69 3GE, Liverpool, UK
176 schema:name Professor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, L69 3GE, Liverpool, UK
177 rdf:type schema:Organization
178 grid-institutes:grid.5072.0 schema:alternateName Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
179 The Royal Marsden NHS Foundation Trust, London, UK
180 schema:name Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
181 The Royal Marsden NHS Foundation Trust, London, UK
182 rdf:type schema:Organization
183 grid-institutes:grid.7700.0 schema:alternateName Professor of Surgery, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
184 schema:name Professor of Surgery, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...